STEM CELL THERAPEUTIC

MEDIPOST acquires patents on the “Mesenchymal Stem Cell Culture Method” in 6 European countries

Significant increase in the revenue of MEDIPOST stem cell therapeutics CARTISTEM in comparison to the previous year

MEDIPOST Obtains Patent for Stem Cell Culture Medium Technique for Hair Loss Treatment

MEDIPOST’s Alzheimer’s Disease Drug Approved by FDA for Clinical Trials

MEDIPOST Obtains Patent for its ‘CARTISTEM’ Production Technology’ in Six European Countries

MEDIPOST Obtains Patent for Core Alzheimer’s Disease Treatment Technology in Six European Countries

MEDIPOST Obtains Patent for Commercializing High-efficiency Technology to Culture Stem Cell

MEDIPOST Obtains Patent in Canada for its Stem Cell-based Alzheimer’s Disease Treatment Composition

MEDIPOST Obtains Patent for its High-Efficient Technology for Culturing Stem Cells

MEDIPOST Obtains Patent in UK for its Alzheimer’s Disease Treatment Technique that Uses Stem Cells

MEDIPOST Begins Sales of its Stem Cell Drug, ‘CARTISTEM’

Chinese Securities Company Praises MEDIPOST as a “Company with Most Profitable Stem Cell Drug”